• FY2024 revenue impacted by postponed customer deployments
• Carrying record pipeline of sales opportunities into FY2025
• Completed equity raise of €13.3m (A$22.0m) in Q4 2024

Oneview Healthcare Plc reported its FY2024 results, with revenue performance impacted by two postponed customer deployments due to construction delays at one and corporate activity at the other. Despite this, the company is carrying a record pipeline of sales opportunities into FY2025. Oneview also completed an equity raise during Q4 2024, yielding net proceeds of €13.3m (A$22.0m), which strengthened its balance sheet. The company's FY2024 revenue was €9.9m, with recurring revenue of €7.2m, up 9% year-on-year. Gross margin improved to 67% (2023: 66%), while the adjusted EBITDA loss increased to €8.8m (2023: €5.5m loss) due to the impact of the delayed projects and front-loaded investment in headcount to support expected deployment activity. Oneview added 8 major new logos in the United States during 2024, including 3 integrated delivery networks, and extended its Value-Added-Reseller Partnership with Baxter for a further two years until mid-2027, expanding it to include the Canadian market in addition to the US.

Oneview's operational and commercial progress, as well as the growing need for connected patient rooms, is evidenced in its recent customer logo additions. The company's market reputation, experience, capital strength, and longstanding investment in R&D position it to take a leading market share in the US.